StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a report published on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Down 0.5 %

Pulmatrix stock opened at $6.26 on Friday. The firm has a market cap of $22.86 million, a P/E ratio of -2.37 and a beta of 1.52. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $8.44. The business has a fifty day moving average of $5.36 and a two-hundred day moving average of $3.24.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.